Publications by authors named "Marine Freist"
Article Synopsis
- - A survey conducted by the Transplantation Commission of the SFNDT gathered responses from 232 nephrologists across France, Switzerland, and Belgium regarding the management of immunosuppressants (IS) in patients experiencing kidney transplant failure (KTF) between March and June 2023.
- - Findings indicated that a significant number of nephrologists discontinued various IS treatments post-KTF, with 83% stopping antimetabolites, while 39.9% and 25.8% stopped calcineurin inhibitors (CNI) and corticosteroids, respectively. Some nephrologists, however, continued CNI (14%) and corticosteroids (19.1%) long-term, often influenced by patient factors like comor
The impact of immunosuppressive therapy (IS) strategies after kidney transplant failure (KTF) on potential future new grafts is poorly established. We assessed the potential benefit of calcineurin inhibitor (CNI)-based IS maintenance throughout the dialysis period on the outcome of the second kidney transplant (KT). We identified 407 patients who underwent a second KT between January 2008 and December 2018 at four French KT centers.
View Article and Find Full Text PDFArticle Synopsis
- * Eligible candidates must have a calculated panel reactive antibody (cPRA) of 98% or higher, be under 65 years old, have been on the waiting list for at least three years, and have a low risk of biopsy complications.
- * The treatment requires a negative post-Imlifidase crossmatch and a strong negative virtual crossmatch, and patients will undergo a specific immunosuppressive regimen along with ongoing monitoring for donor-specific antibodies and potential rejection.
Background: Immunosuppressive treatment is often interrupted in the first months following kidney transplant failure (KTF) to limit side effects. The aim of this study was to assess the effect of prolonged treatment (PT) of more than 3 months' duration after KTF on HLA sensitization and treatment tolerance.
Methods: We performed a retrospective observational study involving 119 patients with KTF in 3 French kidney transplant centers between June 2007 and June 2017.
Protein energy wasting (PEW) including muscle atrophy is a common complication in chronic hemodialysis patients. The ubiquitin proteasome system (UPS) is the main proteolytic system causing muscle atrophy in chronic kidney disease and proteasome 20S is the catalytic component of the UPS. Circulating proteasome 20S (c20S proteasome) is present in the blood and its level is related to disease severity and prognosis in several disorders.
View Article and Find Full Text PDFIntroduction: Hemolytic uremic syndrome (HUS) in Human Immunodeficiency Virus (HIV)-positive patients has become a rare cause of kidney injury since the era of highly active antiretroviral therapy (HAART). Plasma exchange and antiretroviral therapy were previously recommended but often failed to achieve remission. We report a case of HUS in a HIV-positive patient treated successfully with eculizumab.
View Article and Find Full Text PDF